EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

Rhea-AI Summary

EUDA Health Holdings (NASDAQ: EUDA) repurchased and cancelled in full a warrant issued to Streeterville Capital, eliminating the potential issuance of up to 2,000,000 ordinary shares. The warrant was repurchased on February 27, 2026 for a total purchase price of US$125,000.

As a result, there are no warrants remaining under the November 26, 2025 securities purchase agreement and the related potential dilution has been fully removed.

Positive

• Eliminated potential issuance of up to 2,000,000 ordinary shares
• Repurchase completed on February 27, 2026 for US$125,000

Negative

• Cash outflow of US$125,000 to repurchase the warrant

Key Figures

Warrant share capacity: 2,000,000 ordinary shares Repurchase price: US$125,000 Agreement date: November 26, 2025 +3 more

6 metrics

Warrant share capacity 2,000,000 ordinary shares Maximum issuance under repurchased Streeterville warrant

Repurchase price US$125,000 Total paid on February 27, 2026 to repurchase warrant

Agreement date November 26, 2025 Securities purchase agreement for Streeterville warrant

Amendment dates December 16, 2025; January 13, 2026 Prior amendments to Streeterville warrant before repurchase

Price vs 52-week high -81.18% Distance from 52-week high of $4.30 before this news

1-day move -7.26% Price change in 24h before article publication

Market Reality Check

Price: $0.8091 Vol: Volume 59,256 is below 20...

normal vol

$0.8091 Last Close

Volume Volume 59,256 is below 20-day average 71,705 (relative volume 0.83x). normal

Technical Price 0.8091 trades below 200-day MA 2.48 and far below 52-week high 4.30.

Peers on Argus

Momentum scanner shows 2 sector peers moving down (median move -9.9%), suggestin...

2 Down

Momentum scanner shows 2 sector peers moving down (median move -9.9%), suggesting broader pressure alongside EUDA weakness.

Historical Context

5 past events · Latest: Jan 15 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 15	Warrant amendment	Neutral	-4.2%	Second amendment lowered Streeterville warrant exercise and forced-exercise prices.
Jan 13	Convertible loan deal	Positive	-13.9%	Convertible loan to Shenzhen Inno to fund cGMP facility upgrade in Shenzhen.
Jan 07	Warrant amendment	Neutral	+5.7%	First Streeterville warrant amendment reduced exercise and forced-exercise trigger prices.
Dec 30	Platform launch	Positive	+0.0%	Launch of nationwide stem cell extraction, storage and delivery platform in China.
Dec 29	Product launch	Positive	-4.5%	Announcement of EUDA Helixé 2.0 premium vitality and longevity supplement.

Pattern Detected

Recent positive strategic updates have often seen negative or flat next-day reactions, while warrant amendments drew mixed price responses.

Recent Company History

Over the past few months, EUDA issued and repeatedly amended a Streeterville warrant covering up to 2,000,000 ordinary shares, with price cuts detailed in multiple 6-K and 424B5 filings. Other updates included a China stem cell platform launch and a convertible loan to upgrade a Shenzhen cGMP facility, plus the planned Helixé 2.0 supplement launch. Today’s full repurchase and cancellation of the Streeterville warrant removes the potential share issuance previously highlighted in these filings.

Market Pulse Summary

This announcement removes a significant potential issuance of up to 2,000,000 ordinary shares by rep...

Analysis

This announcement removes a significant potential issuance of up to 2,000,000 ordinary shares by repurchasing the Streeterville warrant for US$125,000 and cancelling it. The move follows several prior amendments that had reduced the warrant’s exercise thresholds. Investors may track how this cleaner capital-structure setup interacts with EUDA’s recent China stem cell initiatives, Helixé 2.0 launch plans, and any future financing or growth transactions.

Key Terms

warrant, securities purchase agreement, accredited investor

3 terms

warrant financial

"repurchased and cancelled in full the warrant previously issued to Streeterville"

A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.

securities purchase agreement financial

"the Company entered into a securities purchase agreement dated November 26, 2025"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

accredited investor regulatory

"securities purchase agreement dated November 26, 2025 with an accredited investor"

An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.

AI-generated analysis. Not financial advice.

SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC.

Background of the Warrant

As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and January 13, 2026.

Repurchase and Cancellation

On February 27, 2026, the Company repurchased the warrant in full for a total purchase price of US$125,000. Following the repurchase, the warrant was cancelled and is no longer outstanding.

As a result of this transaction, there are no warrants remaining under this agreement, and the potential issuance of shares associated with the warrant has been fully eliminated.

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Christensen Advisory

Christian Arnell
Phone: +852 2117 0861
Email: christian.arnell@christensencomms.com

FAQ

What did EUDA announce about the Streeterville warrant on March 4, 2026?

They repurchased and cancelled the Streeterville warrant, eliminating its share issuance potential. According to the company, the warrant was repurchased in full on February 27, 2026 for US$125,000 and is no longer outstanding.

How many shares could the repurchased EUDA warrant have converted into?

The warrant was exercisable into up to 2,000,000 newly issued ordinary shares. According to the company, that potential issuance has been fully eliminated by the repurchase and cancellation.

When did EUDA repurchase and cancel the Streeterville warrant (NASDAQ: EUDA)?

EUDA repurchased the warrant on February 27, 2026 and subsequently cancelled it. According to the company, the cancellation means there are no remaining warrants under that agreement.

What was the cost to EUDA to repurchase the warrant tied to the November 26, 2025 agreement?

The company paid a total purchase price of US$125,000 to repurchase the warrant in full. According to the company, that payment removed the warrant and its potential share issuance.

Does the repurchase of the Streeterville warrant affect EUDA shareholder dilution?

Yes, the repurchase removed a possible source of dilution tied to the warrant. According to the company, the cancellation fully eliminated the potential issuance of the warrant's up to 2,000,000 shares.